Hutchison China Meditech Limited Chi-Med to Attend Upcoming Investor Conferences
11 Mai 2020 - 8:00AM
RNS Non-Regulatory
TIDMHCM
Hutchison China Meditech Limited
11 May 2020
Press Release
Chi-Med to Attend Upcoming Investor Conferences
London: Friday, May 11, 2020: Hutchison China MediTech Limited
(" Chi-Med ") (Nasdaq/AIM: HCM) today announces that Mr Christian
Hogg, Chief Executive Officer of Chi-Med, will participate in a
virtual fireside chat at the Bank of America 2020 Health Care
Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight
Time (EDT).
The discussion will be webcast live and can be accessed at
www.chi-med.com in the Shareholder Information section under
"Events, Circulars & Forms." Investors interested in listening
to the live webcast should log on before the start time to download
any software required. A replay of the event will be available
shortly thereafter for approximately 90 days.
Members of the senior management team will also attend virtual
one-on-one meetings at the Bank of America Health Care Conference
on May 14, as well as during the following other conferences:
-- Citi Virtual Pan-Asia Regional Investor Conference from
Tuesday to Thursday, May 19 to 21, 2020;
-- Jefferies Virtual Global Healthcare Conference from Tuesday
to Thursday, June 2 to 4, 2020; and
-- Goldman Sachs Global Healthcare Conference Webcast from
Tuesday to Thursday, June 9 to 11, 2020.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical
company committed, over the past twenty years, to the discovery and
global development of targeted therapies and immunotherapies for
the treatment of cancer and immunological diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world and extensive commercial infrastructure in
its home market of China. For more information, please visit:
www.chi-med.com .
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97
83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAMZGGKRRZGGZG
(END) Dow Jones Newswires
May 11, 2020 02:00 ET (06:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024